Begoña Martin-Castillo

Nom:
Begoña Martin
Firma: Begoña Martin-Castillo
Posició:
Col·laboradors

Cancer stem cell-driven efficacy of trastuzumab (Herceptin): towards a reclassification of clinically HER2-positive breast carcinomas.

Cancer stem cell-driven efficacy of trastuzumab (Herceptin): towards a reclassification of clinically HER2-positive breast carcinomas.

Clinically HER2+ (cHER2+) breast cancer (BC) can no longer be considered a single BC disease entity in terms of trastuzumab responsiveness.

Undefined
Llegir mes

Cytokeratin 5/6 fingerprinting in HER2-positive tumors identifies a poor prognosis and trastuzumab-resistant Basal-HER2 subtype of breast cancer

Cytokeratin 5/6 fingerprinting in HER2-positive tumors identifies a poor prognosis and trastuzumab-resistant Basal-HER2 subtype of breast cancer

There is an urgent need to refine the prognostic taxonomy of HER2+ breast carcinomas and develop easy-to-use, clinic-based prediction algorithms to distinguish between good- and poor- responders to trastuzumab-based therapy.

Undefined
Llegir mes

Anti-protozoal and anti-bacterial Antibiotics that inhibit protein synthesis kill Cancer subtypes enriched for stem cell-like properties.

Anti-protozoal and anti-bacterial Antibiotics that inhibit protein synthesis kill Cancer subtypes enriched for stem cell-like properties.

Key players in translational regulation such as ribosomes might represent powerful, but hitherto largely unexplored, targets to eliminate drug-refractory cancer stem cells (CSCs).

Undefined
Llegir mes
Subscriure a Begoña Martin-Castillo